← All trials
NCT03606096
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2018
- Primary completion
- Sep 30, 2021
- Completion date
- Sep 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 600
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LondonLead sponsor
- National Institute for Public Health and the Environment, RIVM, HollandCollaborator
- Leiden UniversityCollaborator
- Radboud UniversityCollaborator
- University of OxfordCollaborator
- University of TurkuCollaborator
- University of LondonOverall official - principal investigator
- Imperial College LondonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.